분자농업의 현황 및 전망
Current status in molecular farming
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Molecular farming is production of pharmaceutically and industrially important proteins in plants. Plants and plant cell culture systems have been used as bio-factory to produce recombinant proteins such as monoclonal antibodies, enzymes, vaccines, hormones, interleukins, commercial enzymes and etc. The terms molecular farming,biofarming, molecular pharming, hytomanufacturing, recombinant or plant-made industrials, planta-pharma, plant bioreactors, plant biofactory, and pharmaceutical gardening are used interchangeably. Molecular farming can provide safe and inexpensive harmaceutical proteins as well as commercial ones. In spite of several dvantages of molecular farming such as safety and inexpensive cost, there are also a couple of drawbacks in the existing technology. One of them is low expression level of target gene in plants, which has been improved by optimizing gene-based codon usage, screening of strong promoters, expression of transcription factors, subcellular targeting of target proteins, chloroplast transformation, and transient expression using viral expression system (magnifection). Some plant-based commercial proteins have already been in markets and more than twenty plant-based pharmaceuticals have been in clinical trials, from that we can expect that several plant-based pharmaceutical proteins will be seen in the markets in the near future.
Abstract
Molecular farming is production of pharmaceutically and industrially important proteins in plants. Plants and plant cell culture systems have been used as bio-factory to produce recombinant proteins such as monoclonal antibodies, enzymes, vaccines, hormones, interleukins, commercial enzymes and etc. The terms molecular farming,biofarming, molecular pharming, hytomanufacturing, recombinant or plant-made industrials, planta-pharma, plant bioreactors, plant biofactory, and pharmaceutical gardening are used interchangeably. Molecular farming can provide safe and inexpensive harmaceutical proteins as well as commercial ones. In spite of several dvantages of molecular farming such as safety and inexpensive cost, there are also a couple of drawbacks in the existing technology. One of them is low expression level of target gene in plants, which has been improved by optimizing gene-based codon usage, screening of strong promoters, expression of transcription factors, subcellular targeting of target proteins, chloroplast transformation, and transient expression using viral expression system (magnifection). Some plant-based commercial proteins have already been in markets and more than twenty plant-based pharmaceuticals have been in clinical trials, from that we can expect that several plant-based pharmaceutical proteins will be seen in the markets in the near future.
참고문헌 (34)
- Bae JL, "Induction of antigen-specific systemic and mucosal immune responses by feeding animals transgenic plants expressing the antigen", Vaccine, 8, pp.4052~4058 (2003)
- Barta A, "The expression of a nopaline synthase human growth hormone chimeric gene in transformed tobacco and sunflower callus tissue", Plant Mol Biol, 6, pp.347~357 (1986)
- Basaran P, "Plant molecular farming:Opportunities and challenges", Crit Rev Biotechnol, 28, pp.153~172 (2008)
- Bock R, "Transgenic plastids in basic research and plant biotechnology", J Mol Biol, 312, pp.425~438 (2001)
- Commandeur U, "The biosafety of molecular farming in plants", AgBiotechNet, 30, pp.109~112 (2003)
- Daniell H, "Chloroplast-derived vaccine antigens and other therapeutic proteins", Vaccine, 23, pp.1779~1783 (2005)
- De Jaeger G, "Boosting heterologous protein production in transgenic dicotylodonous seeds using Phaseolus vulgaris regulatory sequences", Nat Biotechnol, 20, pp.1265~1268 (2002)
- De Zoeten GA, "The expression, localization, and effect of a human interferon in plants", Virology, 172, pp.213~222 (1989)
- Doran PM, "Foreign protein degradation and instability in plants and plant tissue cultures", Trends Biotechnol, 24, pp.426~432 (2006)
- Gleba Y, "Magnifection-a new platform for expressing recombinant vaccines in plants", Vaccine, 23, pp.2042~2048 (2007)
- Haq TA, "Oral immunization with a recombinant bacterial antigen produced in transgenic plants", Science, 268, pp.714~716 (1995)
- Hiatt A, "Production of antibodies in transgenic plants", Nature, 342, pp.76~78 (1989)
- Horn ME, "Plant molecular farming: systems and products", Plant Cell Rep, 22, pp.711~720 (2004)
- Ibrahim AF, "Expression of intron-containing GUS constructs is reduced due to activation of a crytic 5' splice site", Mol Genet Genomics, 265, pp.455~460 (2001)
- Kang TJ, "Enhanced expression of B-subunit of Escherichia coli heatlabile enterotoxin in tobacco by optimization of coding sequence", Appl Biochem Biotechnol, 117, pp.175~187 (2004)
- Kang TJ, "Expression of the synthetic neutralizing epitope gene of porcine epidemic diarrhea virus in tobacco plants without nicotine", Vaccine, 23, pp.2294~2297 (2005)
- Karg SR, "The production of biopharmaceuticals in plant systems", Biotechnol Adv, 27, pp.879~894 (2009)
- Kim TG, "Expression and immunogenicity of enterotoxigenic Escherichia coli heat-labile toxin B subunit in transgenic rice callus", Mol Biotechnol, 44, pp.14~21 (2009)
- Kim YS, "Expression and assembly of cholera toxin B subunit (CTB) in transgenic carrot (Daucus carota L.)", Mol Biotechnol, 41, pp.8~14 (2009)
- Kumar GB, "Expression of hepatitis B surface antigen in transgenic banana plants", Planta, 222, pp.484~493 (2005)
- Lee KY, "Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria", FEMS Immunol Med Microbiol, 48, pp.381~389 (2006)
- Mason HS, "Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene", Vaccine, 16, pp.1336~1343 (1998)
- Outchkourov NS, "The promoter-terminator of chrysanthemum rbsS1 directs very high expression levels in plants", Planta, 216, pp.1003~ (2003)
- Poirier Y, "Polyhydroxybutyrate, a biodegradable thermoplastic, produced in transgenic plants", Science, 256, pp.520~523 (1992)
- Schillberg S, "Opportunities for recombinant antigen and antibody expression in transgenic plants technology assessment", Vaccine, 23, pp.1764~1769 (2005)
- Shin YJ, "High level of expression of recombinant human granulocyte-macrophage colony stimulating factor in transgenic rice cell suspension culture", Biotechnol Bioeng, 82, pp.778~783 (2002)
- Sijmons PC, "Production of correctly processed human serum albumin in transgenic plants", Bio, 1990, pp.8, 217~221
- Vaquero C, "A carcinoembryonic antigenspecific diabody produced in tobacco", FASEB J, 16, pp.408~410 (2002)
- Walsh J, "Pharmaceuticals, biologics and biopharmaceuticals. in: Biopharmaceuticals: Biochemistry and Biotechnology", pp.1~35 (1998), Wiley
- Yu J, "A plant-based multicomponent vaccine protects mice from enteric diseases", Nat Biotechnol, 19, pp.548~552 (2001)
- Yang MS, "Development and status of plant-based edible vaccine using transgenic plants", BioSafety, 10, pp.44~53 (2009)
- Zhou F, "High-level expression of human immunodeficiency virus antigens from the tobacco and tomato plastid genomes", Plant Biotechnol J, 6, pp.897~913 (2008)
- 농림수산식품 신성장 동력으로서 분자농업의 전망과 과제, "박기영", 농림수산식품기술기획평가원, ~ (2010)